Early-stage Diagnostics 3i Diagnostics specializes in rapid identification of infectious microbes within an hour while keeping the sample intact for further testing, presenting a compelling value proposition for hospitals seeking faster diagnosis and targeted therapy to reduce length of stay and antibiotic overuse.

Cost and Care With a mission to reduce care costs and curb overprescribing, there is a clear sales angle to offer cost-per-test savings analyses, bundled diagnostics with workflow integration, and returns on faster targeted treatments for antimicrobial stewardship programs.

SBIR Funded Validation Recent NSF SBIR funding and industry recognition provide social proof of innovation potential; leverage this to engage grant teams, hospital procurement teams, and potential joint ventures highlighting R&D credibility and near-term clinical impact.

Clinical Collaboration Participation in high-profile conferences and accolades suggests readiness for partnerships with clinical laboratories and research networks; target academic medical centers and hospital systems that value cutting-edge diagnostics and streamlined workflows.

Growth Readiness Small team size and revenue under $1M indicate a scalable partnership model with pilot programs, tiered service offerings, and co-development opportunities to expand adoption across similar institutions as the company scales.